Gene Expression Analysis Market

The global gene expression analysis market in terms of revenue was estimated to be worth $4.2 billion in 2024 and is poised to reach $6.2 billion by 2029, growing at a CAGR of 8.1% from 2024 to 2029. The new research study consists of an industry trend analysis of the market. The new research study consists of industry trends, pricing analysis, patent analysis, conference and webinar materials, key stakeholders, and buying behaviour in the market. The expansion of the market is primarily propelled by the rising prevalence of chronic diseases as gene expression analysis plays a crucial role in understanding the genetic basis of these diseases, enabling personalized medicine approaches for more effective treatments.. The rising pipeline of newer targeted drug therapies is also supporting the growth of this market.

Gene Expression Analysis Market Size, Dynamics & Ecosystem

To know about the assumptions considered for the study, Request for Free Sample Report

Global Gene expression analysis market Dynamics

DRIVER: Advancements in gene editing technology

Gene editing technologies are increasingly crucial in gene expression analysis by enabling precise genome manipulation, elucidating regulatory pathways, and deciphering the functional implications of genetic variations. These technologies empower researchers by providing powerful tools to manipulate the genome, interrogate gene function, and dissect regulatory networks. CRISPR-Cas9, CRISPR Interference (CRISPRi), CRISPR Activation (CRISPRa), TALENs (Transcription Activator-Like Effector Nucleases), ZFNs (Zinc Finger Nucleases) are commonly used technologies employed in gene expression analysis to manipulate the genome and study regulatory mechanisms. TALENs (Transcription Activator-Like Effector Nucleases) have experienced remarkable advancements, significantly enhancing their effectiveness and adaptability across diverse applications. These advancements include refined TALEN design, resulting in heightened DNA-binding precision and reduced off-target effects. Through optimizing TALE repeat structures and amino acid residues, researchers have bolstered the accuracy of TALEN-mediated DNA modifications, thereby enhancing safety protocols and instilling confidence in genomic editing procedures. Additionally, the introduction of multiplex genome editing strategies has revolutionized the efficiency and scope of genetic modifications. This capability enables simultaneous targeting of multiple genomic loci within a single cell, streamlining processes and reducing time investments. Thus, increasing investments in technological advancements in CRISPR-based tools are expected to drive the surge in demand for gene expression analysis in the coming years.

RESTRAINT: High costs of instruments & consumables

The escalating cost of instruments and consumables in gene expression analysis presents formidable obstacles for research and healthcare institutions, hindering their capacity to conduct studies and deliver services efficiently. Complex technologies like microarrays and next-generation sequencing platforms, coupled with the specialized reagents needed for RNA extraction and amplification, contribute to the high expense. Instruments such as microarrays and next-generation sequencing platforms require sophisticated technology and precision engineering, contributing to high initial costs. Moreover, the evolution of genomic technologies necessitates ongoing R&D investments to innovate and improvise existing instruments and methodologies. These factors collectively contribute to the rising cost of instruments and consumables in gene expression analysis, posing challenges for research institutions, healthcare providers, and industry stakeholders alike, thereby restraining market growth to a certain extent.

OPPORTUNITY: Growing focus on Single-Cell Analysis

In recent years, the field of gene expression analysis has experienced a notable shift towards an intensified focus on single-cell analysis techniques. This strategic emphasis stems from recognizing the inherent limitations of traditional bulk RNA sequencing methodologies, which often aggregate gene expression data across large populations of cells, thereby obscuring the intricate heterogeneity and dynamic behavior within cellular ecosystems.

Single-cell RNA sequencing (scRNA-seq) has emerged as a transformative tool, enabling researchers to dissect and elucidate the complex gene expression profiles of individual cells with unprecedented resolution. The significance of single-cell analysis extends beyond mere academic curiosity, finding practical applications across diverse domains, including biotechnology, pharmaceuticals, and healthcare. Understanding the intricacies of cellular behavior at the single-cell level holds immense value for businesses operating in these sectors. For instance, in drug discovery and development, the ability to discern subtle variations in gene expression across different cell types and disease states can inform target identification, drug efficacy assessments, and personalized treatment strategies. Also, within clinical diagnostics, single-cell analysis offers a powerful tool for biomarker discovery, disease subtyping, and patient stratification, paving the way for more precise and tailored therapeutic interventions.

CHALLENGE: Data interpretation challenges

Data interpretation in gene expression analysis is a complex and multifaceted challenge. These challenges stem from the intricate nature of biological systems, variability in experimental techniques, and the sheer volume of data generated during analysis. Biological complexity is a fundamental challenge in interpreting gene expression data. Biological systems operate through intricate networks of genes, proteins, and regulatory pathways. Deciphering how changes in gene expression levels relate to specific biological processes requires a deep understanding of molecular biology and cellular physiology. Moreover, biological systems are dynamic and context-dependent, further complicating interpretation efforts.

Global Gene Expression Analysis Industry Ecosystem Analysis

The gene expression analysis market ecosystem comprises raw material suppliers, product & service providers, regulatory authorities, and end users, such as academic & research institutes, pharmaceutical & biotechnology companies, and other end users.

Gene Expression Analysis Market Segmentation & Geographical Spread

To know about the assumptions considered for the study, download the pdf brochure

Reagents & consumables segment held a dominant share in the product & service segment in the gene expression analysis industry

Based on the product & service, the gene expression analysis market has been segmented into reagents & consumables, instruments, and service. In 2023, reagents & consumables segment accounted for the largest share of the market. This is due to reagents & consumables serve as indispensable tools for researchers and laboratories. In sample preparation, reagents are critical for RNA extraction from diverse biological specimens, encompassing cells, tissues, and bodily fluids.

The drug discovery & development segment in the gene expression analysis industry is expected to register fastest growth during the forecast period.

Based on the application, the gene expression analysis market has been segmented into drug discovery & development, clinical diagnostics, and other applications. In 2023, drug discovery & development accounted for the largest market share and is expected to achieve the highest CAGR during the projected period. The key drivers of drug discovery & development in the market include the increasing focus on biologics and precision therapies has further boosted the demand for gene expression analysis in drug development. Biologics, such as monoclonal antibodies and gene therapies, require a deep understanding of gene expression patterns for their development and optimization. Gene expression analysis enables researchers to assess the expression levels of target genes, optimize production processes, and ensure the efficacy and safety of these innovative therapies.

North America accounted for the largest share of the gene expression analysis Industry in 2023

Geographically, the gene expression analysis market is segmented into North America, Europe, Asia Pacific, Latin America, the Middle East, and Africa. North America held the dominant share followed by Europe. The large share of this market can be attributed to the growing focus of researchers on gene expression studies, availability of funding for NGS research, rising R&D expenditure on drug discovery, favorable government support for therapeutic commercialization, and the presence of key players in the region.

Key players in the global gene expression analysis market include Thermo Fisher Scientific Inc (US), Bio-Rad Laboratories Inc. (US), Illumina Inc (US), QIAGEN (Netherlands), F. Hoffmann-La Roche (Switzerland), Revvity (US), PacBio (US), Agilent Technologies Inc (US), Oxford Gene Technology IP Limited (UK), BGI (China), Eurofins Scientific (Luxembourg), Standard BioTools (US), Oxford Nanopore Technologies plc (UK), GenScript (US), Takara Bio Inc (Japan), 10x Genomics (US), Zymo Research Corporation (US) Scope of the Gene Expression Analysis Industry

This report categorizes the gene expression analysis market to forecast revenue and analyze trends in each of the following submarkets:

By Product & Service

• Reagents & Consumables
  • Assays & kits
  • Enzymes
  • DNA chips
  • Others
• Instruments
  • PCR
  • NGS
  • DNA Microarrays
  • Other instruments
• Service
  • Gene Expression Analysis
    • RNA Sequencing Services
    • Other Services
  • Bioinformatics Solutions

By Application

• Drug Discovery & Development
• Clinical Diagnostics
• Other applications

By End User

• Pharmaceutical & Biotechnology Companies
• Academic & Research Institutes
• Other end users

By Region

• North America
  • US
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Rest of Europe (RoE)
• Asia Pacific (APAC)
  • China
  • Japan
  • India
  • Australia
  • South Korea
  • Rest of Asia Pacific (RoAPAC)
• Latin America
  • Brazil
  • Mexico
  • Rest of Latin America (RoLATAM)
• Middle East & Africa
• Middle East
  • GCC Countries
    • Saudi Arabia
    • United Ara Emirates
    • Rest of GCC Countries
  • Rest of Middle East (RoME)
• Africa

Recent Developments of Gene Expression Analysis Industry:

• In May 2023, Thermo Fisher Scientific and Pfizer collaborated to expand localized access to Next-generation Sequencing-based testing for cancer patients in over 30 countries across Latin America, Africa, the Middle East, and Asia.
• In August 2022, Bio-Rad Laboratories Inc. acquired Curiosity Diagnostics to expand its capabilities by inculcating a new generation of rapid PCR systems into its product portfolio.
• In April 2022, Illumina established a new state-of-the-art facility solution center in São Paulo, Brazil, to expand global access to genomics in Latin America. Illumina’s revenue is majorly generated from markets across North America, Europe, the Middle East, and Africa.

Frequently Asked Questions (FAQ):

To speak to our analyst for a discussion on the above findings, click Speak to Analyst